STRATA Skin Sciences, Inc. (NASDAQ: SSKN) announced that its XTRAC 308 nm excimer laser will be added to the clinical treatment portfolio of Johns Hopkins Dermatology, expanding the device’s use for chronic inflammatory and autoimmune skin diseases such as psoriasis, vitiligo, and atopic dermatitis.
The partnership brings Johns Hopkins, a leading academic medical center, into STRATA’s installed base and is expected to increase device utilization and generate recurring procedure revenue. It also positions STRATA to advance evidence‑based dermatologic care and broaden access to its FDA‑cleared phototherapy technology.
CEO Dolev Rafaeli said, “Academic medical centers play a critical role in advancing evidence‑based dermatologic care, an essential component to improving patient outcomes and quality of life. Collaboration with Johns Hopkins and other leading institutions that prioritize both clinical excellence and research innovation underscores the importance of precision treatment strategies in managing inflammatory skin disease while expanding access to targeted, FDA‑cleared phototherapy in these prestigious centers. STRATA Skin Sciences remains committed to partnering with top academic institutions worldwide to support research, education, and access to advanced dermatologic technologies.”
In Q3 2025, STRATA reported revenue of $6.9 million, a 21% decline year‑over‑year, and a net loss of $1.6 million. Gross profit margin fell from 65% to 60% due to a 60% drop in equipment revenue. In Q1 2025, revenue was $6.8 million, up 1% year‑over‑year, with a net loss of $2.4 million. The company’s financial strength rating is distressed and its Piotroski F‑Score is 3, indicating significant headwinds.
Despite these challenges, the Johns Hopkins partnership may help offset revenue pressure by increasing procedure volume and generating recurring revenue. STRATA’s partnership program focuses on treatment fees rather than equipment sales, providing training and marketing support, and aims to expand reimbursement coverage. Recent CMS recognition of expanded CPT codes for dermatologic conditions could further support revenue growth.
STRATA continues to pursue clinical research at Johns Hopkins, leveraging the partnership to support ongoing studies and evidence generation for chronic inflammatory skin diseases. The company’s strategy to build a robust evidence base and secure reimbursement pathways positions it to capitalize on the partnership’s potential.
The company also has a lawsuit against LaserOptek and is working to expand reimbursement codes, but the Johns Hopkins collaboration represents a strategic milestone that could enhance STRATA’s market presence and long‑term growth prospects.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.